Business Context and Reporting Period
Company: CryoLife, Inc. (Note: Metadata listed "Artivion, Inc." but the filing text identifies the registrant as CryoLife, Inc.)
Filing Type: Form 10-Q (Unaudited)
Period Ended: March 31, 2002
Business Overview: CryoLife operates two primary segments: Human Tissue Preservation Services (cryopreservation of cardiovascular, vascular, and orthopaedic tissue) and Implantable Medical Devices (BioGlue Surgical Adhesive and bioprosthetic devices).
Auditor Status: The financial statements are unaudited and have not been reviewed by an independent auditor. The Company dismissed Arthur Andersen LLP on April 9, 2002, and appointed Deloitte & Touche, LLP on May 7, 2002. Deloitte is scheduled to review these statements.
Key Financial Metrics
| Metric (in thousands) | Q1 2002 | Q1 2001 |
|---|---|---|
| Total Revenues | $25,471 | $21,432 |
| Net Income | $3,104 | $1,970 |
| Earnings Per Share (Diluted) | $0.16 | $0.10 |
| Gross Margin | $15,173 (59.6%) | $12,327 (57.5%) |
| Operating Cash Flow | ($189) | $1,341 |
| Cash and Cash Equivalents | $6,566 | $15,668 |
| Marketable Securities | $25,057 | $26,483 |
| Total Debt (Current + Long-term) | $10,380 | $15,375 |
| Working Capital | $72,849 | $66,668 |
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 19% to $25.5 million, driven by a 100% increase in BioGlue Surgical Adhesive sales ($4.9M vs $2.4M) following FDA approval in December 2001. Human tissue preservation services revenue grew 9% to $20.2 million.
- Profitability: Net income increased 58% to $3.1 million. The effective tax rate was 34% compared to 32% in the prior year.
- Cash Flow: Operating cash flow turned negative ($189k outflow) compared to a $1.3M inflow in Q1 2001. This was primarily due to increased working capital requirements (receivables and deferred preservation costs) to support sales growth.
- Debt Reduction: Total debt decreased significantly as the $4.4 million convertible debenture was converted into 546,000 shares of common stock on March 4, 2002.
- Cost Structure: Cost of products as a percentage of revenue improved to 44% from 54% due to a favorable product mix shift toward higher-margin BioGlue sales.
Guidance, Outlook, and Risks
- Outlook: Management expects current cash and marketable securities to be sufficient for operating needs for at least the next 12 months. Increased tissue procurement levels are expected to drive modest revenue growth over the longer term as tissues are matched with recipients.
- Strategic Initiatives: The Company is seeking a corporate collaboration or private placement to fund the commercial development of Activation Control Technology (ACT) held by its subsidiary, AuraZyme Pharmaceutical, Inc.
- Risks and Contingencies:
- Auditor Review: There is a risk that the new auditor (Deloitte) may require changes to the financial statements, necessitating an amended 10-Q.
- Liquidity: Future funding requirements depend on FDA approvals for clinical trials and market acceptance of new products. Additional financing may be required beyond the next 12 months.
- Procurement Volatility: While procurement increased significantly, there is no assurance these levels can be maintained.
- Interest Rate Risk: The Company has a variable rate term loan, partially hedged by an interest rate swap agreement.
Investor Verification Checklist
- Auditor Review Outcome: Verify if Deloitte & Touche, LLP has filed an amended 10-Q with adjustments to the unaudited financial statements.
- BioGlue Sustainability: Confirm if the 100% revenue growth in BioGlue is sustainable following the initial FDA approval surge.
- Working Capital Trends: Monitor the trend of "Deferred preservation costs" and "Trade receivables" to ensure they convert to cash flow as expected.
- ACT Funding Status: Check for updates on the search for a corporate collaboration or private placement for the AuraZyme subsidiary.
- Debt Covenants: Verify continued compliance with the restrictive covenants of the Term Loan, specifically the minimum tangible net worth requirement.